Open AccessTamoxifen can reverse multidrug resistance of colorectal carcinomain vivo
Author(s) -
Lizong Shen,
Yibing Hua,
XiaoJuan Yu,
Qing Xu,
Tao Chen,
Jianhua Wang,
Wei Wu
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i7.1060
Subject(s) - tamoxifen , in vivo , estrogen receptor , doxorubicin , carcinoma , medicine , breast carcinoma , colorectal cancer , multiple drug resistance , immunohistochemistry , biology , oncology , drug resistance , breast cancer , chemotherapy , cancer , microbiology and biotechnology
To investigate the effect of tamoxifen (TAM) on multidrug resistance (MDR) of colorectal carcinoma in vivo and its relationship with estrogen receptor (ER).